- Yeganeh Z, Sheikhan Z, Hajian P, Esteki T, Nasiri M, Khodakarami N. Relationship between duration of breast feeding and endometrial cancer: a case-control study. The Iranian Journal of Obstetrics, Gynecology and Infertility 2020; 23(8):58-65.
- Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic oncology research and practice 2017; 4:1-12.
- Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. International Journal of Gynecologic Cancer 2016; 26(1).
- Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. New England Journal of Medicine 2003; 348(17):1625-38.
- Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecologic oncology 2013; 129(2):277-84.
- Sari A, Pollett A, Eiriksson LR, Lumsden-Johanson B, Van de Laar E, Kazerouni H, et al. Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas. The American Journal of Surgical Pathology 2019; 43(5):591-600.
- McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer 2016; 122(18):2787-98.
- Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA: a cancer journal for clinicians 2019; 69(4):258-79.
- Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Current Oncology 2008; 15(3):126-35.
- MacKay HJ, Freixinos VR, Fleming GF. Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options. American Society of Clinical Oncology Educational Book 2020; 40:245-55.
- Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. American Society of Clinical Oncology Educational Book 2020; 40:238-44.
- Keller MD, Neppl C, Irmak Y, Hall SR, Schmid RA, Langer R, et al. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. Modern pathology 2018; 31(1):101-10.
- Sungu N, Yildirim M, Desdicioglu R, Aydoğdu ÖB, Kilicarslan A, Doğan HT, et al. Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer. International Journal of Gynecological Pathology 2019; 38(5):404-13.
- Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International immunology 1996; 8(5):765-72.
- Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine 2016; 8(328):328rv4-.
- Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell reports 2017; 20(8):1818-29.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews cancer 2012; 12(4):252-64.
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine 2002; 8(8):793-800.
- Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer 2016; 16(5):275-87.
- Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. International immunology 2016; 28(7):339-48.
- Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences 2008; 105(8):3005-10.
- Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. Journal of clinical pathology 2018; 71(3):189-94.
- Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget 2017; 8(63):106169-70.
- Ono R, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, Ishikawa M, et al. Dedifferentiated endometrial carcinoma could be a target for immune checkpoint inhibitors (anti PD-1/PD-L1 antibodies). International Journal of Molecular Sciences 2019; 20(15):3744.
- Post CC, Westermann AM, Bosse T, Creutzberg CL, Kroep JR. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Critical Reviews in Oncology/Hematology 2020; 152:102973.
- Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA oncology 2015; 1(9):1319-23.
- Liu J, Liu Y, Wang W, Wang C, Che Y. Expression of immune checkpoint molecules in endometrial carcinoma. Experimental and Therapeutic Medicine 2015; 10(5):1947-52.
- Hecking T, Thiesler T, Halbe J, Otten L, Recker F, Gevensleben H, et al. Programmed cell death ligand-1 (PDL-1) correlates with tumor infiltration by immune cells and represents a promising target for immunotherapy in endometrial cancer. Anticancer Research 2022; 42(3):1367-76.
- Engerud H, Berg HF, Myrvold M, Halle MK, Bjorge L, Haldorsen IS, et al. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic oncology 2020; 157(1):260-7.
- Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Modern Pathology 2019; 32(3):396-404.
- Tawadros AI, Khalafalla MM. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma. Journal of cancer research and therapeutics 2018; 14(Suppl 5):S1063-9.
- Li Z, Joehlin-Price AS, Rhoades J, Ayoola-Adeola M, Miller K, Parwani AV, et al. Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency. International Journal of Gynecologic Cancer 2018; 28(1).
- Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, et al. Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer. Oncology letters 2016; 12(2):944-50.
- Lu L, Li Y, Luo R, Xu J, Feng J, Wang M. Prognostic and clinicopathological role of PD-L1 in endometrial cancer: a meta-analysis. Frontiers in Oncology 2020; 10:632.
- Zhang C, Yang Q. Predictive values of programmed cell death-ligand 1 expression for prognosis, clinicopathological factors, and response to programmed cell death-1/programmed cell death-ligand 1 inhibitors in patients with gynecological cancers: a meta-analysis. Frontiers in Oncology 2021; 10:572203.
- Mamat@ Yusof MN, Chew KT, Kampan N, Abd. Aziz NH, Md Zin RR, Tan GC, et al. PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis. Cancers 2022; 14(16):3911.
- Maiorano BA, Maiorano MF, Cormio G, Maglione A, Lorusso D, Maiello E. How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. Frontiers in Oncology 2022; 12:844801.
|
